Fisher Asset Management LLC Sells 1,929 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Fisher Asset Management LLC cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 130,255 shares of the medical equipment provider’s stock after selling 1,929 shares during the quarter. Fisher Asset Management LLC owned approximately 0.06% of Zimmer Biomet Holdings worth $15,252,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bronfman E.L. Rothschild L.P. grew its stake in shares of Zimmer Biomet Holdings by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock worth $106,000 after purchasing an additional 167 shares during the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Zimmer Biomet Holdings by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock worth $112,000 after purchasing an additional 33 shares during the last quarter. BB&T Investment Services Inc. bought a new stake in shares of Zimmer Biomet Holdings in the second quarter worth about $144,000. Parallel Advisors LLC grew its stake in shares of Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after purchasing an additional 199 shares during the last quarter. Finally, IHT Wealth Management LLC grew its stake in shares of Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after purchasing an additional 256 shares during the last quarter. 85.80% of the stock is currently owned by institutional investors.

Several research firms recently issued reports on ZBH. Piper Jaffray Companies cut Zimmer Biomet Holdings from an “overweight” rating to a “neutral” rating in a research note on Thursday, November 2nd. Oppenheimer Holdings, Inc. set a $137.00 price objective on Zimmer Biomet Holdings and gave the company a “buy” rating in a research report on Monday, August 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, November 3rd. Edward Jones raised Zimmer Biomet Holdings from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $120.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, November 3rd. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $134.00.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/11/zimmer-biomet-holdings-inc-zbh-shares-sold-by-fisher-asset-management-llc.html.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) traded down $1.09 during midday trading on Friday, reaching $110.75. 973,400 shares of the company were exchanged, compared to its average volume of 1,366,571. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The stock has a market cap of $22,643.58, a price-to-earnings ratio of 13.86, a P/E/G ratio of 1.74 and a beta of 1.17. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.83 billion. During the same quarter in the previous year, the firm earned $1.79 earnings per share. Zimmer Biomet Holdings’s revenue was down .8% on a year-over-year basis. equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.04 earnings per share for the current year.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply